Priyanka C Iyer
Overview
Explore the profile of Priyanka C Iyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bronk J, Augustyn A, Mohamed A, Fuller C, Garden A, Moreno A, et al.
Radiother Oncol
. 2024 Nov;
202():110602.
PMID: 39489425
Background: The aim of this study is to characterize the patterns of loco-regional progression (LRP) and outcomes after definitive-dose intensity modulated radiation therapy (IMRT) for anaplastic thyroid cancer (ATC) with...
2.
Hamidi S, Dadu R, Zafereo M, Ferrarotto R, Wang J, Maniakas A, et al.
JAMA Oncol
. 2024 Jul;
10(9):1264-1271.
PMID: 38990526
Importance: BRAF/MEK inhibitors revolutionized the treatment of BRAF V600E-variant anaplastic thyroid carcinoma (BRAFv-ATC), offering improved outcomes for patients with this previously incurable disease. Observations: Anaplastic thyroid carcinoma (ATC) accounts for...
3.
Iyer P, Dadu R, Barque A, Zanelli C, Zheng X, Jiang H, et al.
J Clin Endocrinol Metab
. 2024 Mar;
109(9):2269-2273.
PMID: 38441247
Context: Telomerase reverse transcriptase (TERT) promoter-mutated thyroid cancers are associated with a decreased rate of disease-free and disease-specific survival. High-quality analytical validation of a diagnostic test promotes confidence in the...
4.
Hamidi S, Iyer P, Dadu R, Gule-Monroe M, Maniakas A, Zafereo M, et al.
Thyroid
. 2024 Jan;
34(3):336-346.
PMID: 38226606
The dabrafenib plus trametinib combination (DT) has revolutionized the treatment of -mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a...
5.
Hamidi S, Hofmann M, Iyer P, Cabanillas M, Hu M, Busaidy N, et al.
Front Endocrinol (Lausanne)
. 2023 Jul;
14:1176731.
PMID: 37435488
The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs) has undergone major advancements in the last decade, causing a paradigm shift in the management and prognosis of these patients....
6.
Jeun R, Iyer P, Best C, Lavis V, Varghese J, Yedururi S, et al.
Immunotherapy
. 2023 Apr;
15(6):417-428.
PMID: 37013834
Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a rare adverse event. In this study, we characterize clinical outcomes of patients with ICI-DM and evaluate survival impact of this complication on...
7.
Iyer P, Cote G, Hai T, Gule-Monroe M, Bui-Griffith J, Williams M, et al.
JCO Precis Oncol
. 2022 Feb;
2.
PMID: 35135166
Purpose: Anaplastic thyroid cancer (ATC) is a deadly form of thyroid cancer. V600E is the only actionable mutation for which there is a Food and Drug Administration-approved drug combination. Rapid...
8.
Nguyen H, Shah K, Waguespack S, Hu M, Habra M, Cabanillas M, et al.
Endocr Relat Cancer
. 2021 Apr;
28(7):419-431.
PMID: 33890870
Data on the diagnosis, natural course and management of immune checkpoint inhibitor (ICI)-related hypophysitis (irH) are limited. We propose this study to validate the diagnostic criteria, describe characteristics and hormonal...
9.
Iyer P, Cabanillas M, Waguespack S, Hu M, Thosani S, Lavis V, et al.
Thyroid
. 2018 Aug;
28(10):1243-1251.
PMID: 30132401
Background: Although immune-related thyroiditis (irT) with immune checkpoint inhibitors (ICI) is a common consequence, its natural course and management recommendations are not well characterized in existing guidelines. This study sought...
10.
Iyer P, Dadu R, Gule-Monroe M, Busaidy N, Ferrarotto R, Habra M, et al.
J Immunother Cancer
. 2018 Jul;
6(1):68.
PMID: 29996921
Background: Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer. Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC, however, eventually these...